Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation.
The findings of our initial study demonstrate for the first time the ability to terminate induced VT/VF reliably (100% of all episodes) by a single, monophasic 230-J shock delivered by the Wearable Cardioverter-Defibrillator (WCD). Although limited by sample size, our data suggest the WCD could be used as a feasible bridge to definitive implantation of an implantable cardioverter-defibrillator in patients in whom risk stratification for sudden death is not completed.
Auricchio
A
A
Division of Cardiology, University Hospital, Magdeburg, Germany.
Klein
H
H
Geller
C J
CJ
Reek
S
S
Heilman
M S
MS
Szymkiewicz
S J
SJ
D000368:Aged; D004554:Electric Countershock / Q000295:instrumentation; D015716:Electrocardiography, Ambulatory; D005260:Female; D006323:Heart Arrest / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012306:Risk; D014693:Ventricular Fibrillation / Q000628:therapy*